Prevention of wheezing episodes and asthma in high risk children with ketotifeno

Descripción del Articulo

With the purpose to assess the prophylactic effectiveness of Ketotifen in the prevention of the development of wheezing episodes in non-asthmatic children clasified in a high-risk category according to a previousley prepared scale, two groups of 21 children, both similar with respect to age, sex and...

Descripción completa

Detalles Bibliográficos
Autores: Freyre Roman, Eleodoro, Rebaza Gonzales, Rodolfo
Formato: artículo
Fecha de Publicación:1992
Institución:Colegio Médico del Perú
Repositorio:Acta Médica Peruana
Lenguaje:español
OAI Identifier:oai:amp.cmp.org.pe:article/1705
Enlace del recurso:https://amp.cmp.org.pe/index.php/AMP/article/view/1705
Nivel de acceso:acceso abierto
Materia:Desarrollo de sibilancias
asma bronquial
ketotifeno
id REVCMP_616301c535277e8950bb79f39ee2ea42
oai_identifier_str oai:amp.cmp.org.pe:article/1705
network_acronym_str REVCMP
network_name_str Acta Médica Peruana
repository_id_str .
spelling Prevention of wheezing episodes and asthma in high risk children with ketotifenoPrevención del desarrollo de Sibilancias y de Asma Bronquial en niños de alto riesgo con KetotifenoFreyre Roman, Eleodoro Rebaza Gonzales, Rodolfo Desarrollo de sibilanciasasma bronquialketotifenoWith the purpose to assess the prophylactic effectiveness of Ketotifen in the prevention of the development of wheezing episodes in non-asthmatic children clasified in a high-risk category according to a previousley prepared scale, two groups of 21 children, both similar with respect to age, sex and risk rating, were studied. The children of one group received ketotifen and those of the other group did not, both groups being followed during a 12-month period to estimate the development of wheeziness during that time.  The enviromental factors at home, such as the presence of smokers, pets, carpeted floors, and the number of siblings under 10 years of age, were similar in both groups.  A high correlation between the risk rating and the number of episodes of wheeziness in the group not treated with ketotifeno was encountered, thus confirming the value of the scale used.  In the group trated with ketotifen there was a significant lower number of children affected by wheeziness and also of the numer of wheezing episodes for the group as compared with the non-treated group. The differences became more obvious from the third mont of follow-up.  It is concluded that ketotifeno is effective in reducing the development of wheeziness in high-risk, non-asthmatic, and its use is recommended. Con el propósito de evaluar la eficacia profiláctica del Ketotifeno en la prevención del desarrollo ulterior de episodios de sibilancias en niños no asmáticos, pero de alto riesgo según una escala elaborada con anterioridad, se estudiaron dos grupos de 21 años cada uno, similares entre sí respecto a la edad, distribución por sexo y puntaje de riesgo al inicio del estudio. A los niños de uno de los grupos se les administró Ketotifeno y a los del otro no, siguiéndoseles durante 12 meses para estimar el desarrollo de sibilancias en ese período.  Se investigó, también, la frequencia de factores ambientales del hogar como la presencia de fumadores, de animales domésticos, de cuartos alfombrados y el número de hermanos menores de 10 años. Estos factores fueron similares en ambos grupos. Al encontrarse una alta correlación entre el puntaje de riesgo y el número de episodios de sibilancias en el grupo no tratado con Ketotifeno, se confirmó el valor de la escala empleada.  El grupo tratado con Ketotifeno presentó un número significativamente menor de niños que hicieron sibilancias y de episodios de sibilancias para el grupo, siendo las diferencias más marcadas a partir del tercer mes de seguimiento.  Se concluye que el Ketotifeno es eficaz reduciendo el desarrollo de sibilancias en niños no asmáticos de alto riesgo y se recomienda su uso. Colegio Médico del Perú1992-06-30info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://amp.cmp.org.pe/index.php/AMP/article/view/170510.35663/amp.1992.162.1705ACTA MEDICA PERUANA; Vol. 16 No. 2 (1992); 93-99ACTA MEDICA PERUANA; Vol. 16 Núm. 2 (1992); 93-991728-59171018-8800reponame:Acta Médica Peruanainstname:Colegio Médico del Perúinstacron:CMPspahttps://amp.cmp.org.pe/index.php/AMP/article/view/1705/1103Copyright (c) 2020 ACTA MEDICA PERUANAinfo:eu-repo/semantics/openAccessoai:amp.cmp.org.pe:article/17052024-10-04T23:23:52Z
dc.title.none.fl_str_mv Prevention of wheezing episodes and asthma in high risk children with ketotifeno
Prevención del desarrollo de Sibilancias y de Asma Bronquial en niños de alto riesgo con Ketotifeno
title Prevention of wheezing episodes and asthma in high risk children with ketotifeno
spellingShingle Prevention of wheezing episodes and asthma in high risk children with ketotifeno
Freyre Roman, Eleodoro
Desarrollo de sibilancias
asma bronquial
ketotifeno
title_short Prevention of wheezing episodes and asthma in high risk children with ketotifeno
title_full Prevention of wheezing episodes and asthma in high risk children with ketotifeno
title_fullStr Prevention of wheezing episodes and asthma in high risk children with ketotifeno
title_full_unstemmed Prevention of wheezing episodes and asthma in high risk children with ketotifeno
title_sort Prevention of wheezing episodes and asthma in high risk children with ketotifeno
dc.creator.none.fl_str_mv Freyre Roman, Eleodoro
Rebaza Gonzales, Rodolfo
author Freyre Roman, Eleodoro
author_facet Freyre Roman, Eleodoro
Rebaza Gonzales, Rodolfo
author_role author
author2 Rebaza Gonzales, Rodolfo
author2_role author
dc.subject.none.fl_str_mv Desarrollo de sibilancias
asma bronquial
ketotifeno
topic Desarrollo de sibilancias
asma bronquial
ketotifeno
description With the purpose to assess the prophylactic effectiveness of Ketotifen in the prevention of the development of wheezing episodes in non-asthmatic children clasified in a high-risk category according to a previousley prepared scale, two groups of 21 children, both similar with respect to age, sex and risk rating, were studied. The children of one group received ketotifen and those of the other group did not, both groups being followed during a 12-month period to estimate the development of wheeziness during that time.  The enviromental factors at home, such as the presence of smokers, pets, carpeted floors, and the number of siblings under 10 years of age, were similar in both groups.  A high correlation between the risk rating and the number of episodes of wheeziness in the group not treated with ketotifeno was encountered, thus confirming the value of the scale used.  In the group trated with ketotifen there was a significant lower number of children affected by wheeziness and also of the numer of wheezing episodes for the group as compared with the non-treated group. The differences became more obvious from the third mont of follow-up.  It is concluded that ketotifeno is effective in reducing the development of wheeziness in high-risk, non-asthmatic, and its use is recommended. 
publishDate 1992
dc.date.none.fl_str_mv 1992-06-30
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://amp.cmp.org.pe/index.php/AMP/article/view/1705
10.35663/amp.1992.162.1705
url https://amp.cmp.org.pe/index.php/AMP/article/view/1705
identifier_str_mv 10.35663/amp.1992.162.1705
dc.language.none.fl_str_mv spa
language spa
dc.relation.none.fl_str_mv https://amp.cmp.org.pe/index.php/AMP/article/view/1705/1103
dc.rights.none.fl_str_mv Copyright (c) 2020 ACTA MEDICA PERUANA
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2020 ACTA MEDICA PERUANA
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Colegio Médico del Perú
publisher.none.fl_str_mv Colegio Médico del Perú
dc.source.none.fl_str_mv ACTA MEDICA PERUANA; Vol. 16 No. 2 (1992); 93-99
ACTA MEDICA PERUANA; Vol. 16 Núm. 2 (1992); 93-99
1728-5917
1018-8800
reponame:Acta Médica Peruana
instname:Colegio Médico del Perú
instacron:CMP
instname_str Colegio Médico del Perú
instacron_str CMP
institution CMP
reponame_str Acta Médica Peruana
collection Acta Médica Peruana
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1845247455704121344
score 13.424744
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).